BioInvent: Updated Interim Results from BI-1206 in Lymphoma - Redeye
Redeye comments on the December 11 interim results presented at ASH from the phase I/IIa trial of BI-1206 together with rituximab in relapsed indolent lymphoma.
ANNONS
Redeye comments on the December 11 interim results presented at ASH from the phase I/IIa trial of BI-1206 together with rituximab in relapsed indolent lymphoma.